In summary, we have completed a comprehensive evaluation of cystatin C as a candidate ALS biomarker, including assessments of two complementary measures of cystatin C in two distinct biofluids as well as examinations of both longitudinal CSF samples and patient survival data. This evidence concerns the gene CST3 and amyotrophic lateral sclerosis.